What to know about braking the barriers to colorectal cancer care for Black patients, who are estimated to be 20% more likely to receive a colorectal cancer diagnosis than any other racial or ethnic group.
Access to care for the highly preventable disease is thought to be behind why Black Americans are 20% more likely to receive a colorectal cancer diagnosis than any other racial or ethnic group.
BETHESDA, Md. (BUSINESS WIRE) Precision Biologics, Inc. (“Precision”), a clinical-stage immunotherapy and targeted oncology company, announced today the successful completion of the safety phase and the enrollment of new patients into the expansion of the Phase 2 Clinical Trial Combining Precision Biologics NEO-20.